B. Solomon

发表

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014, The New England journal of medicine.

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2012 .

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

M. Varella‐Garcia, B. Solomon, D. Camidge, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

J. Engelman, Michael Thomas, A. Shaw, 2014, The New England journal of medicine.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data

I. Petersen, S. Haas, M. Vingron, 2015, Genome Biology.

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

K. Cibulskis, J. Shendure, G. Getz, 2012, Nature Genetics.

A Genomics-Based Classification of Human Lung Tumors

G. Getz, S. Carter, D. Hayes, 2013, Science Translational Medicine.

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

R. Fisher, S. Fox, B. O'Sullivan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, P. Jänne, 2010, The New England journal of medicine.

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2011, The Lancet. Oncology.

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2012, Science Translational Medicine.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

F. Cappuzzo, T. Mok, Yi-long Wu, 2014, The New England journal of medicine.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Benjamin Solomon, Neal I. Lindeman, Dara L. Aisner, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Michael Thomas, Takashi Seto, Kazuhiko Nakagawa, 2013, The New England journal of medicine.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer

A. Iafrate, A. Shaw, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.

A. Shaw, E. Felip, B. Solomon, 2015 .

A community-based model of rapid autopsy in end-stage cancer patients

Anthony T Papenfuss, Mohammed Madadin, Mark Shackleton, 2016, Nature Biotechnology.

Robyn L. Temple-Smolkin, M. Ladanyi, Christina B. Ventura, 2018, Archives of pathology & laboratory medicine.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Thromboprophylaxis for lung cancer patients—multimodality assessment of clinician practices, perceptions and decision support tools

B. Solomon, S. Kirsa, D. Ball, 2014, Supportive Care in Cancer.

Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?

B. Solomon, A. Thai, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity

J. Trapani, B. Solomon, K. Kedzierska, 2020, Nature Immunology.

Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.

A. Shaw, S. Ou, Gregory Riely, 2012 .

Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non–small cell lung cancer

S. Fox, B. Solomon, P. Russell, 2017, Science Signaling.

Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.

L. Lipton, J. Desai, A. Scott, 2010 .

A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806

A. Scott, B. Solomon, P. Ansell, 2021, The Journal of Nuclear Medicine.

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review

P. Iyengar, B. Solomon, A. Louie, 2021, Translational lung cancer research.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

A. Drilon, J. Neal, H. Wakelee, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.

P. Angenendt, H. Wakelee, L. Sequist, 2013 .

Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma

B. Solomon, W. Alexander, Ashley P Ng, 2020, Oncogene.

MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Jeffrey W. Clark, A. Drilon, M. Socinski, 2017 .

O10.3Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M

J. Neal, H. Wakelee, L. Sequist, 2015 .

TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival

B. Solomon, Y. Haupt, S. Haupt, 2020, Cancers.

Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma

B. Solomon, D. Rischin, Lachlan McDowell, 2020, Clinical and translational radiation oncology.

p16‐positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high‐risk human papillomavirus or prognosis and implications for the workup of the unknown primary

B. Solomon, D. Rischin, Lachlan McDowell, 2016, Cancer.

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

H. Wakelee, L. Sequist, B. Solomon, 2014 .

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma

R. Fisher, S. Fox, B. Solomon, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Prognostic stratification of HPV associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomised trials.

B. Solomon, D. Rischin, J. Dunn, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study.

B. Solomon, D. Rischin, S. Porceddu, 2020, Oral oncology.

Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma.

P. Savas, B. Solomon, C. Cooper, 2019, Oral oncology.

Identification of an excellent prognosis subset of human papillomavirus associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance.

S. Loi, P. Savas, B. Solomon, 2019, Annals of Oncology.

Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma

S. Fox, B. Solomon, S. Hendry, 2018, Cancer Immunology Research.

Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus–positive oropharyngeal squamous cell carcinoma

B. Solomon, L. Peters, D. Rischin, 2016, Head & neck.

Correlation of p16 status, hypoxic imaging using [18F]‐misonidazole positron emission tomography and outcome in patients with loco‐regionally advanced head and neck cancer

R. Fisher, B. Solomon, L. Peters, 2014, Journal of medical imaging and radiation oncology.

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).

H. Wakelee, L. Sequist, S. Ou, 2015 .

Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum.

F. Hirsch, D. Carbone, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The In fl uence of Comorbidity and the Simpli fi ed Comorbidity Score on Overall Survival in Non – Small Cell Lung Cancer — A Prospective Cohort Study

B. Solomon, R. Wolfe, D. Ball, 2017 .

The Influence of Comorbidity and the Simplified Comorbidity Score on Overall Survival in Non–Small Cell Lung Cancer—A Prospective Cohort Study

B. Solomon, R. Wolfe, D. Ball, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment response in the neck: p16+ versus p16− oropharyngeal cancer

B. Solomon, L. Peters, R. Hicks, 2013, Journal of medical imaging and radiation oncology.

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Jeffrey W. Clark, A. Iafrate, S. Fox, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

R. Fisher, S. Fox, B. Solomon, 2010 .

Prognostic Signiﬁcance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

S. Fox, B. O'Sullivan, B. Solomon, 2010 .

Phase lb/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).

Hung-Ming Wang, M. Ahn, B. Solomon, 2014 .

A New Theranostic Paradigm for Advanced Thyroid Cancer

B. Solomon, R. Hicks, D. Pattison, 2016, The Journal of Nuclear Medicine.

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

N. Pavlakis, K. O'Byrne, B. Solomon, 2021, Journal for ImmunoTherapy of Cancer.

Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome.

S. Fox, B. Solomon, P. Russell, 2013, Oral oncology.

Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome

B. Solomon, H. Do, A. Dobrovic, 2014, Clinical Epigenetics.

Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.

P. Bunn, B. Solomon, 2005, Future oncology.

An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer

B. Solomon, I. Davis, M. Rosenthal, 2009, American journal of clinical oncology.

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

A. Shaw, T. Mok, Yi-long Wu, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

S. Digumarthy, A. Iafrate, L. Chirieac, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of ALK-positive nonsmall cell lung cancer: recent advances

B. Solomon, A. Thai, 2017, Current opinion in oncology.

Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells

B. Solomon, G. McArthur, P. Neilsen, 2011, Molecular Cancer Research.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

Martin Vingron, Thomas Zander, Yupeng Cun, 2018, Nature Communications.

Comprehensive genomic profiles of small cell lung cancer

Martin Vingron, Jan O. Korbel, Lucia Anna Muscarella, 2015, Nature.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

Imaging of molecular target modulation in oncology: challenges of early clinical trials

B. Solomon, R. Hicks, C. Cullinane, 2014, Clinical and Translational Imaging.

Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy

B. Solomon, M. Jefford, L. Mileshkin, 2021, Journal of Cancer Survivorship.

Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

A. Bottomley, A. Shaw, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

Jeffrey W. Clark, S. Ou, R. Salgia, 2010 .

Visual Disturbances in Patients (PTS) with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib

A. Shaw, R. Salgia, K. Wilner, 2012 .

3030 POSTER Preliminary Characterization of Visual Events Reported by Patients (Pts) Receiving Crizotinib for the Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

R. Salgia, K. Wilner, B. Solomon, 2011 .

Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2013 .

Navigating Through New, First-Line Treatment Options for Lung Cancer.

B. Solomon, 2018, Journal of oncology practice.

Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding.

K. Rogers, B. Solomon, S. Heynemann, 2021, Pathology.

Abstract 1531: Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets

Roman K. Thomas, T. Zander, E. Brambilla, 2014 .

DNA sequencing and gene-expression profiling assists in making a tissue of origin diagnosis in cancer of unknown primary

R. Tothill, A. deFazio, B. Solomon, 2022, medRxiv.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

M. Erlander, J. Neal, H. Wakelee, 2016 .

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

A. Shaw, T. Mok, E. Felip, 2020, The New England journal of medicine.

ArticleTP53 Status

B. Solomon, Y. Haupt, S. Haupt, 2020 .

Nuclear protein in testis carcinoma: a diagnostic and therapeutic challenge

B. Solomon, G. Hanna, Manu Juneja, 2021, Internal medicine journal.

Radiotherapy and immunotherapy: a synergistic effect in cancer care

G. Turgeon, B. Solomon, S. Siva, 2018, The Medical journal of Australia.

Immunotherapy in oncogene addicted non-small cell lung cancer

B. Solomon, T. John, J. L. Leal, 2020, Translational lung cancer research.

Registrational results of LOXO-292 in patients with RET-altered thyroid cancers

A. Drilon, T. Owonikoko, B. Solomon, 2019, Annals of Oncology.

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations

A. Drilon, A. Graber, B. Solomon, 2021, Molecular Cancer Therapeutics.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, B. Solomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

A. Drilon, Keunchil Park, S. Novello, 2021 .

Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer.

A. Drilon, Keunchil Park, S. Novello, 2020, Future oncology.

of Personalized Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer

B. Solomon, F. Kelleher, G. McArthur, 2012 .

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

Jie Yang, N. Pavlakis, Y. Yatabe, 2022, Clinical lung cancer.

Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin.

B. Solomon, C. Arthur, H. Prince, 2001, European journal of cancer.

Abiraterone in metastatic salivary duct carcinoma.

B. Solomon, D. Rischin, I. D'Costa, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.

A. Shaw, S. Ou, Gregory Riely, 2018 .

Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.

A. Iafrate, A. Shaw, B. Yeap, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC.

B. Solomon, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806

A. Scott, B. Solomon, P. Ansell, 2013, The Journal of Nuclear Medicine.

Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease.

A. Shaw, S. Ou, B. Solomon, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1225OOVERALL AND INTRACRANIAL (IC) EFFICACY RESULTS AND TIME TO SYMPTOM DETERIORATION IN PROFILE 1014: 1ST-LINE CRIZOTINIB VS PEMETREXED - PLATINUM CHEMOTHERAPY (PPC) IN PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC).

T. Mok, K. Wilner, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.

A. Shaw, B. Solomon, Dong-Wan Kim, 2015, Blood.

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

F. Cappuzzo, T. Mok, Yi-long Wu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer.

B. Solomon, R. Pearson, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.

P. Gibbs, J. Desai, B. Solomon, 2017 .

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

J. Desai, K. Flaherty, B. Goh, 2016 .

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.

B. Solomon, Dong-Wan Kim, Geoffrey Liu, 2022, Lung cancer.

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.

A. Shaw, S. Peters, E. Felip, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.

B. Solomon, D. Rischin, S. Porceddu, 2017, International journal of radiation oncology, biology, physics.

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Functional and patient‐reported changes in swallowing and voice after combined chemotherapy and radiotherapy for limited‐stage small‐cell lung cancer

B. Solomon, S. Siva, D. Ball, 2020, Journal of medical imaging and radiation oncology.

Defining Resistance Mechanisms to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer (editorial re: Lin et al.).

B. Solomon, L. Tan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pitfalls and progress in adrenocortical carcinoma diagnosis: the utility of a multidisciplinary approach, immunohistochemistry and genomics

B. Solomon, S. Luen, A. Gill, 2021, Endocrinology, diabetes & metabolism case reports.

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.

A. Shaw, E. Felip, F. de Marinis, 2022, Lung cancer.

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

B. Solomon, J. Jassem, Geoffrey Liu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

P. Jänne, A. Shaw, T. Mok, 2017, ESMO Open.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

F. Cappuzzo, T. Mok, Yi-long Wu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.

B. Solomon, L. Peters, R. Hicks, 2013, Oral oncology.

Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma.

S. Fox, B. Solomon, L. Peters, 2012, Oral oncology.

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.

A. Shaw, T. Mok, Yi-long Wu, 2022, The Lancet. Respiratory medicine.

Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas

E. Zotenko, R. Pidsley, S. Clark, 2015, Clinical Epigenetics.

Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.

Serafino Pantano, Michael Thomas, A. Shaw, 2016 .

Combined Pan‐HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study

G. Giaccone, P. Jänne, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

J. Engelman, A. Shaw, B. Yeap, 2015, Clinical Cancer Research.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

S. C. Wang, A. Iafrate, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Head and Neck Squamous Cell Carcinoma

R. Fisher, S. Fox, B. Solomon, 2020, Definitions.

Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome

S. Fox, B. Solomon, H. Do, 2014, International journal of cancer.

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

L. Kats, B. Solomon, I. Parish, 2021, Nature Communications.

Lung cancer

L. Sequist, R. Heist, B. Solomon, 2021, The Lancet.

Immunotherapy for Anaplastic Thyroid Carcinoma.

B. Solomon, A. Lim, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease

B. Solomon, M. Bulsara, N. Wong, 2020, Cancer medicine.

FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies

B. Solomon, M. Asselin-Labat, C. Weeden, 2015, Cell Death Discovery.

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

S. Fox, B. Solomon, P. Russell, 2013, Modern Pathology.

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

B. Solomon, J. Zalcberg, M. Jefford, 2018, Cancer Chemotherapy and Pharmacology.

M OLECULAR INSIGHTS INFLUENCING THE MANAGEMENT OF HEAD AND NECK CANCERS

B. Solomon, D. Rischin, A. Lim, 2015 .

CD74-NRG1 fusions in lung adenocarcinoma.

I. Petersen, S. Haas, M. Vingron, 2014, Cancer discovery.

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

A. Iafrate, A. Shaw, R. Salgia, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

B. Solomon, L. Amler, L. Mileshkin, 2011, Clinical Cancer Research.

Imaging , Diagnosis , Prognosis Changes in 18 F-Fluorodeoxyglucose and 18 F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non – Small Cell Lung Cancer Treated with Erlotinib

B. Solomon, L. Amler, L. Mileshkin, 2011 .

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

N. Girard, M. Ahn, Melissa L. Johnson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

M. Stockler, L. Seymour, K. Ding, 2014, European journal of cancer.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Impact of sex on prognostic host factors in surgical patients with lung cancer

B. Solomon, P. Russell, P. Choong, 2017, ANZ journal of surgery.

Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma

B. Solomon, D. Rischin, A. Thai, 2021, Cancers.

Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines.

B. Solomon, P. Beavis, P. Darcy, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.

N. Pavlakis, B. Solomon, A. Gill, 2021, Clinical lung cancer.

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

A. Scott, B. Solomon, J. Simes, 2015, Journal of Clinical Neuroscience.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

A. Shaw, S. Ou, Gregory Riely, 2018, The Lancet. Oncology.

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

J. Desai, L. Galletta, B. Solomon, 2019, Contemporary clinical trials communications.

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data

I. Petersen, S. Haas, M. Vingron, 2015, Genome Biology.

Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer

A. Shaw, K. Wilner, B. Solomon, 2013, Clinical pharmacology and therapeutics.

Anaplastic Lymphoma Kinase

B. Solomon, A. Rao, 2013 .

Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements

S. Fox, B. Solomon, Toni-Maree Rogers, 2012 .

Progress in targeted therapies for cancer: overview

B. Solomon, J. Zalcberg, 2008 .

Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease

B. Solomon, A. Broad, S. Kao, 2021, JCO precision oncology.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

I. Petersen, D. Hayes, M. Wilkerson, 2018, Nature Communications.

Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment.

B. Solomon, L. Tan, 2018, PET clinics.

The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview.

B. Solomon, J. Soria, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.

B. Solomon, D. Rischin, R. Young, 2018, Seminars in cancer biology.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Lucio Crinò, Benjamin Solomon, Patrick Schnell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary

R. Tothill, J. George, A. deFazio, 2022, The Journal of pathology.

Mitogen-activated protein kinase pathway inhibition for re-differentiation of radioiodine-refractory differentiated thyroid cancer: an evolving protocol.

B. Solomon, T. Akhurst, R. Hicks, 2019, Thyroid : official journal of the American Thyroid Association.

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

R. Tothill, S. Dawson, P. Lehner, 2019, Cancer cell.

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

A. Drilon, B. Tuch, S. Dawson, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression

B. Solomon, P. Darcy, P. Beavis, 2019, Science Translational Medicine.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Jeffrey W. Clark, A. Iafrate, S. Fox, 2012, The Lancet. Oncology.

Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma

Matthew E. Ritchie, S. Fox, B. Solomon, 2017, Molecular Cancer Therapeutics.

Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH

B. Solomon, P. Russell, M. Conron, 2014, Modern Pathology.

IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.

L. Kats, B. Solomon, R. Johnstone, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.

B. Solomon, V. Jordan, R. Manser, 2022, The Cochrane database of systematic reviews.

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

B. Solomon, V. Jordan, R. Manser, 2019, Cochrane Database of Systematic Reviews.

Sex‐Dependent Staging in Non–Small‐Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System

B. Solomon, P. Russell, P. Choong, 2018, Clinical lung cancer.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.

F. Hodi, S. Gettinger, T. Mok, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

S. C. Wang, A. Iafrate, A. Shaw, 2019 .

Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids

Martin Vingron, Thomas Zander, Viktor Achter, 2014, Nature Communications.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.

M. Ratain, S. Ou, R. Salgia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

H. Wakelee, L. Sequist, S. Ou, 2014 .

Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting

S. Fox, B. Solomon, H. Do, 2008, BMC Research Notes.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.

Serafino Pantano, B. Solomon, D. Camidge, 2021, Lung Cancer.

Frequency and prognostic significance of p16 INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma

B. Solomon, D. Rischin, R. Young, 2015 .

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

F. Cappuzzo, T. Mok, Yi-long Wu, 2014 .

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

F. Cappuzzo, T. Mok, Yi-long Wu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

R. Gray, R. Caprioli, P. Massion, 2007, Journal of the National Cancer Institute.

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

B. Solomon, J. Wolf, S. Dimitrijević, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma

B. Solomon, P. Russell, H. Do, 2017, Medical Oncology.

Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors

B. Solomon, C. Khoo, Tessa A. Morris, 2019, Drugs.

The efficacy of the ALK inhibitor crizotinib as compared with standard chemo- therapy as first-line treatment for advanced ALK-positive non–small-cell lung can-

F. Cappuzzo, T. Mok, Yi-long Wu, 2019 .

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer

B. Solomon, Laird B Cameron, 2015, Current Treatment Options in Oncology.

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

B. Solomon, Laird B Cameron, 2015, Drugs.

Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.

A. Shaw, E. Felip, B. Solomon, 2015 .

Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer

S. Fox, B. Solomon, P. Russell, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Complex renal cysts associated with crizotinib treatment

A. Shaw, Weiwei Tan, K. Wilner, 2015, Cancer medicine.

Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.

B. Solomon, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.

P. Savas, B. Solomon, B. Hughes, 2013, Journal of thoracic disease.

Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer

B. Solomon, F. Kelleher, G. McArthur, 2012, Journal of personalized medicine.

Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both?

A. Shaw, B. Solomon, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting Anaplastic Lymphoma Kinase in Lung Cancer

A. Shaw, B. Solomon, 2011, Clinical Cancer Research.

Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.

B. Solomon, D. Rischin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crizotinib and testing for ALK.

A. Shaw, B. Solomon, M. Kenudson, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

DNA repair pathways and their therapeutic potential in lung cancer

Benjamin Solomon, Derek J. Richard, K. O'Byrne, 2014 .

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

A. Iafrate, A. Shaw, S. Ou, 2010 .

Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.

B. Solomon, P. Russell, M. Conron, 2017, Pathology.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

G. Scagliotti, M. Mino‐Kenudson, J. Engelman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

Jeffrey W. Clark, A. Drilon, R. Heist, 2019, Nature Medicine.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

T. Mok, G. Veronesi, D. Planchard, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.

T. Mok, K. Kerr, G. Veronesi, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer

B. Solomon, R. Wolfe, D. Ball, 2019, Cancers.

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

B. Solomon, G. McArthur, M. Shackleton, 2018, European journal of cancer.

Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non‐small cell lung cancer

B. Solomon, Marco Peters, J. Lewis, 2014, Internal medicine journal.

Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging

B. Solomon, D. Binns, G. McArthur, 2005, Molecular Cancer Therapeutics.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

C. Paweletz, P. Angenendt, H. Wakelee, 2016, Clinical Cancer Research.

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.

S. Fox, N. Pavlakis, K. O'Byrne, 2019, Pathology.

Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non‐small‐cell lung carcinoma

Dishan M. Herath, S. Fox, B. Solomon, 2018, Internal medicine journal.

Custom workflows to improve joint variant calling from multiple related tumour samples: FreeBayesSomatic and Strelka2Pass

Stephen Q. Wong, Sebastian Hollizeck, B. Solomon, 2021, Bioinform..

A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells

J. Desai, A. Scott, B. Solomon, 2015, PloS one.

Robyn L. Temple-Smolkin, M. Ladanyi, Christina B. Ventura, 2018, The Journal of molecular diagnostics : JMD.

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

C. Azzoli, L. Sequist, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer.

B. Solomon, M. Millward, D. Ball, 2003, Lung cancer.

Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics

B. Solomon, J. Zalcberg, G. McArthur, 2012, BioDrugs.

An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009

B. Solomon, J. Szer, S. Kirsa, 2011, Internal medicine journal.

Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations

A. Drilon, B. Solomon, Y. Summers, 2022, ESMO open.

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.

Maarten J. IJzerman, J. Desai, B. Solomon, 2020, Lung cancer.

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

J. Desai, B. Solomon, M. Brown, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians

Maarten J. IJzerman, N. Pavlakis, S. Peters, 2020, ESMO Open.

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

A. Drilon, B. Tuch, T. Mok, 2018, Journal of Thoracic Oncology.

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

A. Drilon, Keunchil Park, Melissa L. Johnson, 2018 .

The current status of targeted therapy for non‐small cell lung cancer

B. Solomon, Benjamin Solomon, H. Francis, 2010, Internal medicine journal.

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.

Tomas Kron, Andrew Wirth, Benjamin Solomon, 2019, The Lancet. Oncology.

Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.

R. Doebele, B. Solomon, A. Baron, 2013, Clinical lung cancer.

A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.

N. Pavlakis, B. Solomon, S. Clarke, 2020, Lung cancer.

IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy.

D. Gandara, S. Peters, R. Dziadziuszko, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

B. Solomon, R. Molania, G. McArthur, 2021, Journal for ImmunoTherapy of Cancer.

First-line treatment options for ALK-rearranged lung cancer

B. Solomon, 2017, The Lancet.

Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy

J. Bedő, B. Solomon, D. Ball, 2015, PloS one.

Frequency and prognostic significance of p16INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma

B. Solomon, D. Rischin, R. Young, 2015, British Journal of Cancer.

Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

P. Jänne, K. O'Byrne, Michael Thomas, 2012 .

EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.

M. Trivett, B. Solomon, G. McArthur, 2003, International journal of radiation oncology, biology, physics.

Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer

B. Solomon, R. Wolfe, D. Ball, 2017, British Journal of Cancer.

Early versus On-Demand Tube Feeding in Pancreatitis

A. Shaw, B. Solomon, 2015 .

Thromboembolism in lung cancer - an area of urgent unmet need.

B. Solomon, S. Kirsa, R. Wolfe, 2014, Lung cancer.

The emerging era of personalized therapy in squamous cell carcinoma of the head and neck

B. Solomon, S. Porceddu, D. Pryor, 2011, Asia-Pacific journal of clinical oncology.

Sex and gender in health research: updating policy to reflect evidence

M. Woodward, S. Peters, W. Rogers, 2019, The Medical journal of Australia.

Thromboembolism in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.

B. Solomon, M. Alexander, K. Burbury, 2018, Clinical lung cancer.

Clinical Management of Adverse Events Associated with Lorlatinib.

A. Shaw, E. Felip, B. Solomon, 2019, The oncologist.

Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer

B. Solomon, Y. Haupt, S. Haupt, 2017, Molecular & cellular oncology.

A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC

B. Solomon, L. Mileshkin, D. Ball, 2005, British Journal of Cancer.

Differential 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models

J. Christensen, B. Solomon, D. Binns, 2011, The Journal of Nuclear Medicine.

ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2017 .

Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

Benjamin Solomon, A. Shaw, E. Felip, 2016 .

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non–Small-Cell Lung Cancer

B. Solomon, D. Ball, J. Bar, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

P. Bunn, B. Solomon, 2007, Cancer investigation.

Adjuvant chemotherapy for resected non-small-cell lung cancer.

P. Bunn, B. Solomon, John D Mitchell, 2005, Oncology.

Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.

B. Solomon, L. Mileshkin, D. Ball, 2013, Clinical lung cancer.

Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study.

A. Shaw, C. Chiu, B. Solomon, 2021 .

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

A. Shaw, S. Ou, Gregory Riely, 2019, The Lancet. Oncology.

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.

J. Moffat, T. Ketela, K. Brown, 2015, Cancer research.

Treatment of ALK‐rearranged non‐small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

N. Pavlakis, B. Solomon, M. Millward, 2017, Asia-Pacific journal of clinical oncology.

Finding chinks in the osimertinib resistance armor

B. Solomon, T. John, J. L. Leal, 2020, Translational lung cancer research.

Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

D. Chakrabarti, A. Shaw, E. Felip, 2018 .

Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by 18F-FLT PET/CT in Patients with Locally Advanced Non–Small Cell Lung Cancer

B. Solomon, D. Ball, R. Hicks, 2014, The Journal of Nuclear Medicine.

Advanced Non F-FLT PET / CT in Patients with Locally 18 Marrow and Spleen , Estimated by Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone

B. Solomon, D. Ball, R. Hicks, 2014 .

BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.

G. Taylor, B. Solomon, G. McArthur, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Development of a hospital-based patient-reported outcome framework for lung cancer patients: a study protocol

B. Solomon, L. Mileshkin, D. Ball, 2018, Health and Quality of Life Outcomes.

Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells.

B. Solomon, G. McArthur, Y. Haupt, 2014, International journal of radiation oncology, biology, physics.

Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of Clinical Oncology.

Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity.

P. Bunn, B. Solomon, 2005, Cancer treatment reviews.

Unilateral radiotherapy treatment for p16/human papillomavirus–positive squamous cell carcinoma of unknown primary in the head and neck

B. Solomon, D. Rischin, R. Young, 2018, The Laryngoscope.

Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors

J. Desai, B. Solomon, M. Brown, 2016 .

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

C. Dooms, Toshio Shimizu, R. Heist, 2022, Cancer Research.

Preoperative chemotherapy for non-small-cell lung cancer

B. Solomon, G. Hanna, S. Siva, 2014, The Lancet.

Identifying Mechanisms of Resistance to ALK Tyrosine Kinase Inhibitors Using Analysis of Circulating Tumor DNA.

B. Solomon, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.

A. Shaw, S. Peters, E. Felip, 2020, Lung cancer.

Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.

S. Ou, K. Wilner, B. Solomon, 2020, Lung cancer.

OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

S. C. Wang, A. Drilon, R. Heist, 2018, Journal of Thoracic Oncology.

FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).

A. Drilon, S. Novello, B. Solomon, 2021 .

OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer

A. Shaw, S. Ou, E. Felip, 2017 .

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

A. Drilon, Keunchil Park, B. Solomon, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).

A. Drilon, Keunchil Park, B. Solomon, 2021 .

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types.

B. Solomon, D. Yardley, A. Drakaki, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Response to Mahe

B. Solomon, W. Cooper, 2014, Modern Pathology.

Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study.

A. Shaw, S. Ou, E. Felip, 2017 .

Lung Cancer in Australia.

B. Solomon, W. Cooper, K. Fong, 2020, Journal of Thoracic Oncology.

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.

Keunchil Park, O. Burghuber, Yuh-Min Chen, 2023, Future oncology.

Contribution Co-targeting Deoxyribonucleic Acid e Dependent Protein Kinase and Poly ( Adenosine Diphosphate-Ribose ) Polymerase-1 Promotes Accelerated Senescence of Irradiated Cancer Cells

B. Solomon, G. McArthur, C. Cullinane, 2014 .

Molecular insights influencing the management of head and neck cancers

B. Solomon, D. Rischin, A. Lim, 2015 .

Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.

A. Iafrate, J. Engelman, K. Bergethon, 2010 .

Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC).

F. Cappuzzo, T. Mok, K. Wilner, 2015 .

Suicide in lung cancer: who is at risk?

B. Solomon, D. Neiger, L. Mileshkin, 2013, Chest.

LBA50Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014

T. Mok, K. Wilner, E. Felip, 2017 .

Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).

S. Gettinger, Gregory Riely, B. Solomon, 2013 .

First-line crizotinib in ALK-positive lung cancer.

B. Solomon, T. Mok, Benjamin J Solomon, 2015, The New England journal of medicine.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial

Michael Thomas, A. Shaw, Gregory Riely, 2016 .

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Absence of a Relationship between Tumor 18F-fluorodeoxyglucose Standardized Uptake Value and Survival in Patients Treated with Definitive Radiotherapy for Non–Small-Cell Lung Cancer

B. Solomon, D. Binns, R. Fisher, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy

D. Gandara, S. Peters, B. Solomon, 2018, Journal of Thoracic Oncology.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, Y. Bang, 2019 .

Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.

A. Shaw, S. Ou, R. Salgia, 2012 .

LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

A. Shaw, T. Mok, E. Felip, 2020 .

MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC

A. Shaw, T. Mok, E. Felip, 2021 .

Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.

A. Drilon, B. Solomon, J. Wolf, 2020 .

Current highlights in lung cancer in 2021

B. Solomon, K. Lim, 2021, ESMO Open.

Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma

B. Solomon, J. A. Heath, Alison S. Thomas, 2018, Pediatric blood & cancer.

Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer

B. Solomon, R. Wolfe, D. Ball, 2019, Cancers.

OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6

A. Shaw, S. Ou, Gregory Riely, 2018, Journal of Thoracic Oncology.

Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC).

S. Tenn, B. Solomon, M. Steinberg, 2023, International journal of radiation oncology, biology, physics.

Multicenter randomized, open‐label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first‐line therapy in elderly or ECOG PS two patients with advanced NSCLC

B. Solomon, S. Clarke, H. Do, 2015, Asia-Pacific journal of clinical oncology.

Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.

R. Doebele, B. Solomon, D. Gerber, 2016 .

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

A. Shaw, B. Solomon, 2015, The New England journal of medicine.

Suicide in lung cancer: who is at risk?

B. Solomon, D. Neiger, L. Mileshkin, 2013, Chest.

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

A. Shaw, T. Mok, Yi-long Wu, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

M. Erlander, M. Socinski, J. Neal, 2018, JCO precision oncology.

Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".

B. Solomon, Jessica J. Lin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer

B. Solomon, I. Davis, M. Rosenthal, 2009, American journal of clinical oncology.

Crizotinib and testing for ALK.

A. Shaw, B. Solomon, M. Kenudson, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer

A. Shaw, B. Solomon, J. Martini, 2018, Journal of Thoracic Oncology.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

G. Scagliotti, M. Mino‐Kenudson, J. Engelman, 2021 .

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014

F. Cappuzzo, T. Mok, Yi-long Wu, 2018 .

IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.

L. Kats, B. Solomon, R. Johnstone, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients

Gretchen Purcell Jackson, Benjamin Solomon, Marliese Alexander, 2020, JAMIA open.

A community-based model of rapid autopsy in end-stage cancer patients

Samantha E. Boyle, Gisela Mir Arnau, D. Bowtell, 2016, Nature Biotechnology.

Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

A. Shaw, S. Peters, E. Felip, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

B. Solomon, J. Wolf, S. Dimitrijević, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA07.11 Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC)

A. Shaw, B. Solomon, A. Abbattista, 2017 .

In Replay: Psychiatric Morbidity in Patients with Lung Cancer.

B. Solomon, D. Neiger, L. Mileshkin, 2014, Chest.